{"id":"W4295259533","doi":"10.1016/j.jaad.2022.06.343","title":"33270 Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Plaque psoriasis; Open label; Interim analysis; Interim; Term (time); Psoriasis; Dermatology; Adverse effect; Surgery; Randomized controlled trial; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004135197,0.0009957122,0.002463069,0.0003344817,0.0003769869,0.001477692,0.0006507278,0.00100831,0.00382935],"category_scores_gemma":[0.002366851,0.0004426251,0.003116291,0.0003428163,0.0007131423,0.0009737608,0.0004172205,0.002988438,0.001146824],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006127128,"about_ca_system_score_gemma":0.001008476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006953063,"about_ca_topic_score_gemma":0.001097586,"domain_scores_codex":[0.9985403,0.0007275526,0.00006705934,0.0001707051,0.0001942244,0.0003002154],"domain_scores_gemma":[0.9985587,0.0005733949,0.0003480976,0.0001898543,0.0001193303,0.0002106699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9235583,0.004738363,0.006317113,0.000513417,0.002862234,0.0001117557,0.00007115528,0.002101099,0.009072457,0.0002083624,0.002723129,0.04772278],"study_design_scores_gemma":[0.5642405,0.3150606,0.09580338,0.0001629918,0.00848463,0.0003418132,0.0000963604,0.004232705,0.005777085,0.0008914783,0.004796434,0.0001120663],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883471,0.004662821,0.0007051978,0.0003575765,0.0001682277,0.0004061626,0.00246866,0.000103617,0.002780705],"genre_scores_gemma":[0.9925957,0.0009358546,0.0004584227,0.0004254823,0.0001593624,0.0004236575,0.00281254,0.00002490258,0.002163932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004135197,"threshold_uncertainty_score":0.02186924,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06921087710824349,"score_gpt":0.3868242283742427,"score_spread":0.3176133512659992,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}